Litgrid AB results for the three months of 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailLithuanian electricity transmission system operator LITGRID AB (company code 302564383, registered office address Karlo Gustavo Emilio Manerheimo str. 8, Vilnius, Lithuania) is publishing results of the Company for the three months of 2024.
| Main financial indicators | Q1 2024 | Q1 2023 |
| Revenue, EUR million | 113.0 | 86.8 |
| EBITDA, EUR million | 29.4 | 19.7 |
| Net profit, EUR million | 21.5 | 12.9 |
| ROE (for the last 12 months), percents | 25.9 | -17,3 |
| Adjusted* EBITDA, EUR million | 12.8 | 9.4 |
| Adjusted* Net profit, EUR million | 7.4 | 4.0 |
| Adjusted* ROE (for the last 12 months), percents | 11.5 | 6.0 |
*The adjustment of income, costs and profitability indicators is carried out due to temporary regulatory difference from the regulated profitability approved by NERC. The indicators are adjusted by the correction of income, which has already been approved by the decision of NERC when the regulated transmission service prices of the reporting period were approved. Also, the indicators are adjusted by the deviation of the NERC-approved (regulated) and actual profitability of the reporting period, which NERC will evaluate when determining the transmission service prices for the coming period.
Attachment:
- Financial report of the Company.
More information:
Jurga Eivaitė
Communications Project Manager
+370 613 19977
[email protected]
Attachment
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Pati
- Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
- Binance Acquires BTEXCHAIN, Accelerating the Integration of AI and Global Digital Asset Trading Technology
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
